Zafgen Announces Pricing of Public Offering of Common Stock Read more about Zafgen Announces Pricing of Public Offering of Common Stock Zafgen Announces Proposed Public Offering of Common Stock Read more about Zafgen Announces Proposed Public Offering of Common Stock Zafgen Announces Positive Results From Phase 2 Clinical Trial of Beloranib in Hypothalamic Injury Associated Obesity Read more about Zafgen Announces Positive Results From Phase 2 Clinical Trial of Beloranib in Hypothalamic Injury Associated Obesity Zafgen Added to NASDAQ Biotechnology Index Read more about Zafgen Added to NASDAQ Biotechnology Index Zafgen Announces Initiation of Phase 2b Trial of Beloranib in Severe Obesity Read more about Zafgen Announces Initiation of Phase 2b Trial of Beloranib in Severe Obesity Zafgen Reports Third Quarter 2014 Financial Results Read more about Zafgen Reports Third Quarter 2014 Financial Results Zafgen to Host Conference Call to Discuss Third Quarter 2014 Financial Results Read more about Zafgen to Host Conference Call to Discuss Third Quarter 2014 Financial Results Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome Read more about Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome Zafgen Completes Enrollment of Phase 2a Trial of Beloranib in Hypothalamic Injury-Associated Obesity Read more about Zafgen Completes Enrollment of Phase 2a Trial of Beloranib in Hypothalamic Injury-Associated Obesity Zafgen to Present at 2014 Leerink Partners Rare Disease Roundtable Read more about Zafgen to Present at 2014 Leerink Partners Rare Disease Roundtable Pagination First page « First Previous page ‹ Previous … Page 16 Page 17 Page 18 Page 19 Current page 20 Page 21 Page 22 Page 23 Page 24 … Next page Next › Last page Last » Subscribe to
Zafgen Announces Pricing of Public Offering of Common Stock Read more about Zafgen Announces Pricing of Public Offering of Common Stock
Zafgen Announces Proposed Public Offering of Common Stock Read more about Zafgen Announces Proposed Public Offering of Common Stock
Zafgen Announces Positive Results From Phase 2 Clinical Trial of Beloranib in Hypothalamic Injury Associated Obesity Read more about Zafgen Announces Positive Results From Phase 2 Clinical Trial of Beloranib in Hypothalamic Injury Associated Obesity
Zafgen Added to NASDAQ Biotechnology Index Read more about Zafgen Added to NASDAQ Biotechnology Index
Zafgen Announces Initiation of Phase 2b Trial of Beloranib in Severe Obesity Read more about Zafgen Announces Initiation of Phase 2b Trial of Beloranib in Severe Obesity
Zafgen Reports Third Quarter 2014 Financial Results Read more about Zafgen Reports Third Quarter 2014 Financial Results
Zafgen to Host Conference Call to Discuss Third Quarter 2014 Financial Results Read more about Zafgen to Host Conference Call to Discuss Third Quarter 2014 Financial Results
Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome Read more about Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome
Zafgen Completes Enrollment of Phase 2a Trial of Beloranib in Hypothalamic Injury-Associated Obesity Read more about Zafgen Completes Enrollment of Phase 2a Trial of Beloranib in Hypothalamic Injury-Associated Obesity
Zafgen to Present at 2014 Leerink Partners Rare Disease Roundtable Read more about Zafgen to Present at 2014 Leerink Partners Rare Disease Roundtable